- ¥910bn
- ¥897bn
- ¥500bn
Table: Sysmex -2019/20 group results (IFRS)
Table: Sysmex -9-MTH group results (IFRS)
Brief: Biolidics Enters Definitive Agreement With Sysmex Corp For Cancer Diagnostics Tests
Table: Sysmex -6-MTH group results (IFRS)
Table: Sysmex -Q1 group results (IFRS)
Table: Sysmex -2018/19 parent results
Table: Sysmex -2018/19 group results (IFRS)
Brief: Biolidics Executes Non-Binding Term Sheet With Sysmex Corp
Table: Sysmex -9-MTH group results (IFRS)
Table: Sysmex -6-MTH group results (IFRS)
Brief: R&I upgrades Sysmex's rating to "AA-" and says stable rating outlook-R&I
Table: Sysmex -Q1 group results (IFRS)
Table: Sysmex -2017/18 group results (IFRS)
Table: Sysmex -9-MTH group results (IFRS)
Table: Sysmex -6-MTH group results (IFRS)
Brief: U.S. FDA clears a complete blood cell count test called XW-100 Automated Hematology Analyzer
Table: Sysmex -Q1 group results (IFRS)
Brief: R&I affirms Sysmex's rating at "A+" and announces positive outlook -R&I
Table: Sysmex -2016/17 group results (IFRS)